Cardiac dysfunction associated with trastuzumab Journal Article
| Authors: | Smith, K. L.; Dang, C.; Seidman, A. D. |
| Article Title: | Cardiac dysfunction associated with trastuzumab |
| Abstract: | The HER2/neu gene is amplified in ∼ 25% of breast cancers, leading to HER2 protein overexpression and shortened overall survival and time to relapse. Trastuzumab is a humanised, monoclonal antibody against HER2, which improves survival for women with metastatic HER2-overexpressing breast cancer and reduces the risk of recurrence in women with early stage HER2-overexpressing breast cancer. Cardiac toxicity was an unexpected finding in the pivotal Phase III trial leading to the approval of trastuzumab, and prospective cardiac monitoring has, therefore, been incorporated into more recent clinical trials of trastuzumab. This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity. © 2006 Informa UK Ltd. |
| Keywords: | cancer survival; overall survival; genetics; clinical trial; review; cancer recurrence; cisplatin; doxorubicin; fluorouracil; monotherapy; drug approval; paclitaxel; chemotherapy, adjuvant; cancer staging; gene overexpression; proto oncogene; metastasis; apoptosis; breast cancer; gene amplification; heart disease; epidermal growth factor receptor 2; cyclophosphamide; patient monitoring; cardiac glycoside; antineoplastic activity; drug effect; breast neoplasms; docetaxel; monoclonal antibody; antibodies, monoclonal; chemically induced disorder; adjuvant chemotherapy; cardiotoxicity; breast tumor; cancer relapse; epirubicin; anthracycline derivative; echocardiography; trastuzumab; navelbine; dna topoisomerase (atp hydrolysing); risk reduction; drug dose regimen; heart left ventricle ejection fraction; genes, erbb-2; dipeptidyl carboxypeptidase inhibitor; congestive heart failure; heart stroke volume; stroke volume; diuretic agent; clinical trials; heart diseases; cardiac toxicity |
| Journal Title: | Expert Opinion on Drug Safety |
| Volume: | 5 |
| Issue: | 5 |
| ISSN: | 1474-0338 |
| Publisher: | Informa Healthcare |
| Date Published: | 2006-09-01 |
| Start Page: | 619 |
| End Page: | 629 |
| Language: | English |
| DOI: | 10.1517/14740338.5.5.619 |
| PUBMED: | 16907652 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 22" - "Export Date: 4 June 2012" - "CODEN: EODSA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work